Completed PHASE3 INTERVENTIONAL NCT00033904

Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer

A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma

Sponsor: Agenus Inc.

Conditions Renal Cell Carcinoma

Interventions autologous human tumor-derived HSPPC-96

Updated 6 times since 2017 Last updated: Sep 6, 2012 Started: Jun 30, 2000 Primary completion: Apr 30, 2007 Completion: Apr 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Renal Cell Carcinoma, this trial is completed. The trial is conducted by Agenus Inc. and has accumulated 6 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Agenus Inc.

Data source: Agenus Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Anchorage, United States , Atlanta, United States , Baltimore, United States , Barcelona, Spain , Beer-Yaacob, Israel , Bialystok, Poland , Boca Raton, United States , Boston, United States , Bristol, United Kingdom and 65 more locations